This article from the University of California Berkeley discusses a breakthrough in CRISPR-Cas9 gene editing technology. Researchers at the University of California, Berkeley, led by Jennifer Hamilton, have developed a method to deliver CRISPR-Cas9 components directly into specific cells in living animals. This advancement could eliminate the need to extract and reinfuse cells, as currently practiced in many gene therapies.

The key innovation involves encapsulating Cas9 proteins and Guide RNAs within membrane bubbles decorated with antibodies. These antibodies target specific types of cells, allowing the CRISPR components to enter and edit the genetic material within those cells. The researchers successfully targeted T-cells in live mice, converting them into cancer-fighting cells, known as CAR T-cells.


This targeted delivery method offers several advantages over traditional approaches. By precisely honing in on specific cell types, it reduces the risk of side effects and lessens the need for genetic engineering outside the body. Furthermore, the encapsulated Cas9 proteins have a shorter lifespan, decreasing the likelihood of unintended genetic modifications.

This breakthrough represents a significant step forward in the field of gene editing, with the potential to revolutionize the treatment of various genetic disorders and diseases.

In AP Bio we learned about RNA processing; gene editing is similar to RNA processing in which segments of RNA (introns) are cut from the RNA while exons are spliced together. This process mirrors the artificial editing that humans developed to insert, delete, or modify genes with precision.





Print Friendly, PDF & Email